J&J's Analgesic Sales Ease Pain Of Ongoing OTC Turnaround
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
CFO Dominic Caruso reaffirms J&J’s commitment to keeping and growing its consumer business as the firm reports its OTC adult analgesic US market share reached 14% while pediatric share was nearly 46%.
You may also be interested in...
Tylenol Relaunch Ads Harken To “Trusted” History
In online video ads for Tylenol, the firm says “for everything we do, we know you do so much more.” CFO Dominic Caruso says the ad campaign will reconnect the brand with consumers.
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.
MoCRA Implementation In US Election Year: Q&A With Attorney Wade Ackerman
Wade Ackerman, partner at Covington & Burling who served previously as senior FDA counsel to US Senate Health Education, Labor & Pensions (HELP) Committee leadership, discusses expectations for FDA activity under modernized cosmetics regulations in 2024.